

S9 Table. The comparison of dosing racemic praziquantel (PZQ) alone, or with drug ‘B’ on PZQ’s antischistosomal efficacy in rodent models. The superscript descriptions show the additional information of the study; (e): Without H₂O, (f): Sudanese population, (g): High oil diet, (h): Low oil diet, (n): Egyptian population not cured after 2nd dose PZQ, (k): Egyptian population, (l): Ureamic patient, (m): Egyptian population not cured after dose PZQ, (i): CIM dosed 1h prior to PZQ, (j): CHQ dosed 2h before PZQ. Unless otherwise stated the following acronyms represent; M: Mouse, H: Hamster, WBR: Worm burden reduction, MEF: Mefloquine, ABT: 1-aminobenzotriazole, ART: Artemether, NIL: Nilutamide, MET: Metrifonate, DEX: Dexamethasone, CLO: Clonazepam, TUM: Turmeric.

Drug Administered	Drug Effect Measured	PZQ Dose (mg/kg)	B Dose (mg/kg)	N	WBR (%)
PZQ [1-5]					
<i>M</i> ^(g) (<i>mansoni</i>)	<i>PZQ</i>	50	-	4	13
<i>M</i> (<i>mansoni</i>)				5	16
<i>H</i> (<i>mansoni</i>)		75		5	2
<i>M</i> ^(g) (<i>mansoni</i>)		100		6	15
<i>M</i> (<i>mansoni</i>)				5	17.8
<i>H</i> (<i>mansoni</i>)				5	36
<i>M</i> (<i>mansoni</i>)	<i>PZQ</i>	200		14	56.6
<i>M</i> (<i>mansoni</i>)	(<i>R</i>)- <i>PZQ</i>			6	68
<i>M</i> (<i>mansoni</i>)		400		6	97
<i>M</i> (<i>mansoni</i>)				4	84
<i>M</i> (<i>mansoni</i>)	<i>PZQ</i>	500		10	95
<i>M</i> (<i>mansoni</i>)		(5 x 12.5)		8	23.07
<i>M</i> (<i>mansoni</i>)		(5 x 25)		8	37.69
<i>M</i> (<i>mansoni</i>)		(5 x 50)		8	65.75
<i>M</i> (<i>mansoni</i>)		(5 x 100)		8	85.75
<i>M</i> (<i>mansoni</i>)		(5 x 200)		8	91.53
PZQ + ABT [1]					
<i>M</i> ^(g) (<i>mansoni</i>)	(<i>R</i>)- <i>PZQ</i>	50	50	2	21
<i>M</i> ^(h) (<i>mansoni</i>)				6	53
<i>M</i> ^(g) (<i>mansoni</i>)		100	20	5	60
<i>M</i> ^(h) (<i>mansoni</i>)			50	5	79
<i>M</i> ^(g) (<i>mansoni</i>)		200	20	5	100
<i>M</i> ^(h) (<i>mansoni</i>)			50	4	88
PZQ + ART [5, 6]					
<i>H</i> ⁽ⁱ⁾ (<i>mansoni</i>)	<i>PZQ</i>	75	150	5	81
<i>H</i> ^(j) (<i>mansoni</i>)				5	84
<i>H</i> ^(k) (<i>mansoni</i>)				5	82
<i>H</i> ^(l) (<i>mansoni</i>)				5	84
<i>H</i> ^(m) (<i>mansoni</i>)				5	77

<i>H</i> ⁽ⁱ⁾ (<i>mansi</i> ni)			5	68	
<i>H</i> ^(j) (<i>mansi</i> ni)			5	76	
<i>H</i> ^(k) (<i>mansi</i> ni)			5	73	
<i>H</i> ^(l) (<i>mansi</i> ni)			5	81	
<i>H</i> ^(k) (<i>mansi</i> ni)	100	300	5	95	
<i>H</i> ^(l) (<i>mansi</i> ni)			5	99	
<i>H</i> ^(m) (<i>mansi</i> ni)			5	92	
<i>H</i> ^(k) (<i>mansi</i> ni)			5	92	
<i>H</i> ^(l) (<i>mansi</i> ni)			5	96	
<i>H</i> ^(m) (<i>mansi</i> ni)			5	90	
<i>M</i> (<i>mansi</i> ni)	(5 x 12.5)	400	8	56.52	
<i>M</i> (<i>mansi</i> ni)	(5 x 25)		8	73.07	
<i>M</i> (<i>mansi</i> ni)	(5 x 50)		8	80.37	
<i>M</i> (<i>mansi</i> ni)	(5 x 100)		8	85.75	
<i>M</i> (<i>mansi</i> ni)	(5 x 200)		8	93.44	
PZQ + CLO ^[2]					
<i>M</i> (<i>mansi</i> ni)	<i>PZQ</i>	200	10	14	61
PZQ + DEX ^[1]					
<i>M</i> ⁽ⁿ⁾ (<i>mansi</i> ni)	(<i>R</i>)- <i>PZQ</i>	400	100	4	73
PZQ + MEF ^[3]					
<i>M</i> ^(e) (<i>mansi</i> ni)	<i>PZQ</i>	42.5	15	4	19.2
<i>M</i> ^(f) (<i>mansi</i> ni)		50	50	8	25
<i>M</i> ^(f) (<i>mansi</i> ni)				8	61.5
<i>M</i> ^(f) (<i>mansi</i> ni)				8	47.8
<i>M</i> ^(e) (<i>mansi</i> ni)		85	30	4	51.6
<i>M</i> ^(f) (<i>mansi</i> ni)		100	100	8	86
<i>M</i> ^(f) (<i>mansi</i> ni)				9	93.1
<i>M</i> ^(f) (<i>mansi</i> ni)				9	54.7
<i>M</i> ^(e) (<i>mansi</i> ni)		170	60	4	91.8
<i>M</i> ^(e) (<i>mansi</i> ni)		340	120	4	97.8
PZQ + MET					
<i>M</i> (<i>mansi</i> ni)		(5 x 100)	(5 x 50)	X	95.1
PZQ + NIL ^[4]					
<i>M</i> (<i>mansi</i> ni)	<i>PZQ</i>	50	100	5	11.7
<i>M</i> (<i>mansi</i> ni)		100	100	5	3.1
<i>M</i> (<i>mansi</i> ni)		100	200	5	90.6
PZQ + TUM ^[7]					
<i>M</i> (<i>mansi</i> ni)	<i>PZQ</i>	500	400	10	100

References

1. Abla N, Keiser J, Vargas M, Reimers N, Haas H, Spangenberg T. Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the schistosoma mansoni mouse model: Possible clinical implications. Tropical Medicine and International Health. 2017;22 (Supplement 1):136-7. doi: <http://dx.doi.org/10.1111/%28ISSN%291365-3156>. PubMed PMID: 618977725.
2. Araujo N, De Mattos ACA, Coelho PMZ, Katz N. Association of oxamniquine praziquantel and clonazepam in experimental Schistosomiasis mansoni. Memorias do Instituto Oswaldo Cruz. 2008;103(8):781-5. PubMed PMID: 354009130.

3. Keiser J, Manneck T, Vargas M. Interactions of mefloquine with praziquantel in the schistosoma mansoni mouse model and in vitro. *Journal of Antimicrobial Chemotherapy*. 2011;66(8):1791-7. doi: <http://dx.doi.org/10.1093/jac/dkr178>. PubMed PMID: 362161771.
 4. Keiser J, Vargas M, Vennerstrom JL. Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. *Journal of Antimicrobial Chemotherapy*. 2010;65(9):1991-5. doi: <http://dx.doi.org/10.1093/jac/dkq233>. PubMed PMID: 359359597.
 5. Utzinger J, Chollet J, You JQ, Mei JY, Tanner M, Xiao SH. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. *Acta Tropica*. 2001;80(1):9-18. doi: 10.1016/s0001-706x(01)00138-3. PubMed PMID: WOS:000170709200002.
 6. Botros SS, Hammam OA, Mahmoud M, Bergquist R. Praziquantel efficacy in mice infected with PZQ non-susceptible *S. mansoni* isolate treated with artemether: Parasitological, biochemical and immunohistochemical assessment. *Apmis*. 2010;118(9):692-702. doi: <http://dx.doi.org/10.1111/j.1600-0463.2010.02645.x>. PubMed PMID: 359413192.
 7. Hussein A, Rashed S, El Hayawan I, El-Sayed R, Ali H. Evaluation of the Anti-schistosomal Effects of Turmeric (*Curcuma longa*) Versus Praziquantel in Schistosoma mansoni Infected Mice. *Iranian Journal of Parasitology*. 2017;12(4):587-96. PubMed PMID: WOS:000418756700014
- .